ARK Investment Management LLC recently announced the acquisition of new stake in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT). The institutional investor has increased its shareholding in the Healthcare company by 22.65% to 1.92 million shares with purchase of 0.35 million shares. This fresh investment now brings its stake to 8.04% valued currently at $100.22 million. In addition, BlackRock Fund Advisors raised its holdings by 0.78 million to 0.86 million shares. And The Vanguard Group, Inc. has lifted its position by 497.30% or 0.69 million shares – to 0.83 million shares.
With over 1.43 million Arcturus Therapeutics Holdings Inc. (ARCT) shares trading Friday and a closing price of $62.65 on the day, the dollar volume was approximately $89.62 million. The shares have shown a positive weekly performance of 29.93% and its price on 08/21/20 gained nearly 6.55%. Currently, there are 18.79M common shares owned by the public and among those 18.78M shares have been available to trade.
An analysis of what Wall Street brokers have to say about the expected price targets for this stock gives us this picture: 10 analysts who have offered their price forecasts for ARCT have a consensus price objective of $71.50. The analysts have set the share’s price value over the next 12 months at a high of $82.00 and a low of $31.00 should the stock experience a downside. Incidentally, analysts’ outlook for the Arcturus Therapeutics Holdings Inc. stock is 1.80 for the next 12 months. The average price target is 5.99% above its last price level and an upside to the estimated low will see the stock lose -102.1% over that period. But an upside of 23.6% will see the stock hit the forecast high price target while mean target price for the stock is $77.50.
Insiders at the company have transacted a total of 5 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 5 of these insider trades were purchases, accounting for 23,449 shares. Insider sales of the common stock occurred on 0 occasions, with total insider shares sold totaling 0 shares.
The top 3 mutual fund holders in Arcturus Therapeutics Holdings Inc. are ARK Genomic Revolution ETF, Fidelity Select Port. – Biotechno, and Federated Hermes Kaufmann Small C. ARK Genomic Revolution ETF owns 2.04 million shares of the company’s stock, all valued at over $106.3 million. The company bought an additional 6642.0 shares recently to bring their total holdings to about 8.53% of the shares outstanding. Federated Hermes Kaufmann Small C bought 0.61 million shares to bring its total holdings to over 0.61 million shares at a value of $32.12 million. Federated Hermes Kaufmann Small C now owns shares totaling to 2.58% of the shares outstanding.
Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) opened at $59.93, up $1.13 from a prior closing price of $58.80. However, the script later closed the day at $62.65, up 6.55%. The company’s stock has a 5-day price change of 29.93% and 7.52% over the past three months. ARCT shares are trading 476.36% year to date (YTD), with the 12-month market performance up to 474.77% higher. It has a 12-month low price of $8.51 and touched a high of $63.45 over the same period. Currently, 1.43 million shares have been traded, compared to an average intraday trading volume of 842.68K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 15.02%, 24.64%, and 136.21% respectively.
Institutional ownership of Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) shares accounts for 52.70% of the company’s 18.79M shares outstanding. Mutual fund holders own 24.19%, while other institutional holders and individual stakeholders account for 30.19% and 10.93% respectively.
It has a market capitalization of $1.43B and a beta (3y monthly) value of 3.29. The earnings-per-share (ttm) stands at -$2.87. Price movements for the stock have been influenced by the stock’s volatility, which stands at 9.15% over the week and 9.23% over the month.
Analysts forecast that Arcturus Therapeutics Holdings Inc. (ARCT) will achieve an EPS of -$0.48 for the current quarter, -$0.52 for the next quarter and $0.29 for 2021. The lowest estimate earnings-per-share for the quarter is -$0.63 while analysts give the company a high EPS estimate of -$0.4. Comparatively, EPS for the current quarter was -$0.68 a year ago. Earnings per share for the fiscal year are expected to increase by 0.50%, and 113.60% over the next financial year.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 10 brokerage firm advisors rate Arcturus Therapeutics Holdings Inc. (ARCT) as a “Strong Buy” at a consensus score of 1.80. Specifically, 7 Wall Street analysts polled rate the stock as a buy, while 1 of the 10 advise that investors “hold,” and 0 rated it as a “Sell.”
Looking at the support for the ARCT, a number of firms have released research notes about the stock. ROTH Capital stated their Buy rating for the stock in a research note on July 30, 2020, with the firm’s price target at $77. Raymond James coverage for the Arcturus Therapeutics Holdings Inc. (ARCT) stock in a research note released on July 16, 2020 offered a Outperform rating with a price target of $72. B. Riley FBR was of a view on July 13, 2020 that the stock is Buy, while WBB Securities gave the stock Hold rating on June 09, 2020, issuing a price target of. Robert W. Baird on their part issued Outperform rating on February 11, 2020.